<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36749990</PMID><DateCompleted><Year>2023</Year><Month>02</Month><Day>09</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>05</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1943-2704</ISSN><JournalIssue CitedMedium="Internet"><Volume>35</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Wounds : a compendium of clinical research and practice</Title><ISOAbbreviation>Wounds</ISOAbbreviation></Journal><ArticleTitle>Leukocyte- and platelet-rich fibrin treatment of chronic lower extremity ulcer in a patient with systemic lupus erythematosus: a case report.</ArticleTitle><Pagination><StartPage>E1</StartPage><EndPage>E6</EndPage><MedlinePgn>E1-E6</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.25270/wnds/21154</ELocationID><Abstract><AbstractText Label="INTRODUCTION">Lower extremity ulcer is a severe complication in patients with autoimmune disease, and treatment is difficult and time-consuming. L-PRF has been widely used in mammalian regenerative medicine owing to its ease of use and low cost. However, few studies have been published on the application of L-PRF in autoimmune-associated ulcers.</AbstractText><AbstractText Label="CASE REPORT">This case report discusses a 26-year-old male patient with SLE who presented to the authors' institution with a chronic lower extremity ulcer of 8 months' duration. He received once-weekly L-PRF treatment along with standard wound care. After 15 treatments, the ulcer was completely epithelialized, with a healing rate of 3.8 cm2 per week.</AbstractText><AbstractText Label="CONCLUSIONS">This case report provides a promising therapeutic strategy for the treatment of autoimmune-associated ulcers. More robust data from case series and RCTs are required to further evaluate the clinical efficacy of L-PRF in refractory ulcers in patients with autoimmune disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Chunyu</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Jing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Fen</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Weili</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Qinqin</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shao</LastName><ForeName>Shiying</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Wounds</MedlineTA><NlmUniqueID>9010276</NlmUniqueID><ISSNLinking>1044-7946</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073183" MajorTopicYN="Y">Platelet-Rich Fibrin</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014456" MajorTopicYN="N">Ulcer</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007871" MajorTopicYN="Y">Leg Ulcer</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001327" MajorTopicYN="Y">Autoimmune Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D035002" MajorTopicYN="N">Lower Extremity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008322" MajorTopicYN="N">Mammals</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>7</Day><Hour>17</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36749990</ArticleId><ArticleId IdType="doi">10.25270/wnds/21154</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>